永安藥業(002365.SZ):擬推出員工持股計劃
格隆匯 10 月 22日丨永安藥業(002365.SZ)公佈,為進一步完善公司治理水平,建立和完善勞動者與所有者的利益共享機制,提高公司員工的凝聚力和競爭力,充分調動員工的積極性和創造性,促進公司可持續發展,依據《公司法》、《證券法》、《關於上市公司實施員工持股計劃試點的指導意見》、《深圳證券交易所上市公司信息披露指引第4 號--員工持股計劃》等有關法律、法規及規範性文件的規定,結合公司實際情況,公司擬推出員工持股計劃。
在符合相關法律法規規定的前提下,本次員工持股計劃持有的公司股票總數累計不超過公司現有已回購的股份總額(即798.86萬股,佔公司總股份比例2.71%),單個員工所獲股份權益對應的股票總數累計不超過公司股本總額的1%。具體規模以後續審議披露的員工持股計劃草案為準。
該員工持股計劃的股票來源為公司回購專用賬户內已回購的股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.